scispace - formally typeset
C

Christel Herold-Mende

Researcher at Heidelberg University

Publications -  370
Citations -  33068

Christel Herold-Mende is an academic researcher from Heidelberg University. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 78, co-authored 313 publications receiving 25616 citations. Previous affiliations of Christel Herold-Mende include University Hospital Heidelberg & German Cancer Research Center.

Papers
More filters
Journal ArticleDOI

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Daniel J. Brat, +306 more
TL;DR: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class.
Journal ArticleDOI

DNA methylation-based classification of central nervous system tumours

David Capper, +171 more
- 22 Mar 2018 - 
TL;DR: This work presents a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and shows that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods.
Journal ArticleDOI

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm, +82 more
- 16 Oct 2012 - 
TL;DR: It is demonstrated that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup.
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.